Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95

A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell (2012) 4.89

The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer (2012) 3.75

Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71

Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer (2013) 2.60

The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res (2011) 2.22

Immune cell promotion of metastasis. Nat Rev Immunol (2015) 2.15

Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08

Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov (2012) 2.07

Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev (2013) 2.05

The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell (2011) 1.92

Tumor promotion via injury- and death-induced inflammation. Immunity (2011) 1.81

Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer (2012) 1.78

Regulatory T cells in nonlymphoid tissues. Nat Immunol (2013) 1.69

Targeting regulatory T cells in cancer. Cancer Res (2011) 1.66

Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. J Exp Med (2013) 1.47

CD105 expression on CD34-negative spindle-shaped stromal cells of primary tumor is an unfavorable prognostic marker in early breast cancer patients. PLoS One (2015) 1.44

Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev (2014) 1.38

Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond. Front Immunol (2014) 1.29

MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw (2011) 1.29

New developments in osteoimmunology. Nat Rev Rheumatol (2012) 1.28

Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol (2011) 1.27

The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Oncoimmunology (2012) 1.26

Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol (2015) 1.24

Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest (2015) 1.24

A NIK-IKKα module expands ErbB2-induced tumor-initiating cells by stimulating nuclear export of p27/Kip1. Cancer Cell (2013) 1.21

Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance. Cancer Microenviron (2012) 1.15

microRNA-mediated regulation of the tumor microenvironment. Cell Cycle (2013) 1.14

Reproductive history and breast cancer risk. Breast Cancer (2012) 1.14

Phosphanegold(I) thiolates, Ph3PAu[SC(OR)=NC 6H 4Me-4] for R = Me, Et and iPr, induce apoptosis, cell cycle arrest and inhibit cell invasion of HT-29 colon cancer cells through modulation of the nuclear factor-κB activation pathway and ubiquitination. J Biol Inorg Chem (2015) 1.13

The immune system and inflammation in breast cancer. Mol Cell Endocrinol (2013) 1.12

Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression. Cancers (Basel) (2014) 1.10

Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines. J Exp Clin Cancer Res (2013) 1.08

Chemokines and chemokine receptors as promoters of prostate cancer growth and progression. Crit Rev Eukaryot Gene Expr (2013) 1.05

Basic principles of tumor-associated regulatory T cell biology. Trends Immunol (2012) 1.05

Paracrine WNT5A Signaling Inhibits Expansion of Tumor-Initiating Cells. Cancer Res (2015) 1.04

Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther (2012) 1.03

Denosumab in patients with cancer-a surgical strike against the osteoclast. Nat Rev Clin Oncol (2012) 1.02

Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res (2013) 1.02

Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers (Basel) (2013) 1.01

Specific recruitment of γδ regulatory T cells in human breast cancer. Cancer Res (2013) 1.01

Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development. PLoS One (2012) 1.00

Integrated Analysis Reveals hsa-miR-142 as a Representative of a Lymphocyte-Specific Gene Expression and Methylation Signature. Cancer Inform (2012) 1.00

Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis (2015) 1.00

LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat Med (2016) 0.99

Galectin-1 research in T cell immunity: past, present and future. Clin Immunol (2011) 0.98

Roadblocks to translational advances on metastasis research. Nat Med (2013) 0.98

Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade. Proc Natl Acad Sci U S A (2014) 0.96

Roles of regulatory T cells in cancer immunity. Int Immunol (2016) 0.95

Targeting RANKL in metastasis. Bonekey Rep (2014) 0.95

Immune system: a double-edged sword in cancer. Inflamm Res (2013) 0.95

Interaction among cells of bone, immune system, and solid tumors leads to bone metastases. Clin Dev Immunol (2013) 0.94

Emerging roles of the tumor-associated stroma in promoting tumor metastasis. Cell Adh Migr (2012) 0.94

From the ranks of mammary progesterone mediators, RANKL takes the spotlight. Mol Cell Endocrinol (2011) 0.94

T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer. PLoS One (2013) 0.94

Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. Clin Exp Metastasis (2015) 0.94

Mouse Rankl expression is regulated in T cells by c-Fos through a cluster of distal regulatory enhancers designated the T cell control region. J Biol Chem (2011) 0.93

Infiltrating T cells promote prostate cancer metastasis via modulation of FGF11→miRNA-541→androgen receptor (AR)→MMP9 signaling. Mol Oncol (2014) 0.93

RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer (2014) 0.93

Effects of RANKL-Targeted Therapy in Immunity and Cancer. Front Oncol (2014) 0.92

In vivo expansion of naïve CD4+ CD25(high) FOXP3+ regulatory T cells in patients with colorectal carcinoma after IL-2 administration. PLoS One (2012) 0.92

RANK expression on breast cancer cells promotes skeletal metastasis. Clin Exp Metastasis (2013) 0.91

Future perspectives of prostate cancer therapy. Transl Androl Urol (2012) 0.91

Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer. Front Immunol (2013) 0.91

Regulatory T cell: a protection for tumour cells. J Cell Mol Med (2012) 0.91

Cancer-derived matrix metalloproteinase-9 contributes to tumor tolerance. J Cancer Res Clin Oncol (2011) 0.89

Roles of tumor suppressors in regulating tumor-associated inflammation. Cell Death Differ (2014) 0.89

Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity. Eur J Immunol (2012) 0.89

Holothurian glycosaminoglycan inhibits metastasis and thrombosis via targeting of nuclear factor-κB/tissue factor/Factor Xa pathway in melanoma B16F10 cells. PLoS One (2013) 0.89

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology (2015) 0.88

Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med (2013) 0.87

The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and regulatory T cells. EMBO Rep (2012) 0.87

The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis. Oncotarget (2015) 0.87

Stromal biomarkers in breast cancer development and progression. Clin Exp Metastasis (2012) 0.86

Harnessing the immune system for the treatment of breast cancer. J Zhejiang Univ Sci B (2014) 0.85

MMP1, MMP9, and COX2 expressions in promonocytes are induced by breast cancer cells and correlate with collagen degradation, transformation-like morphological changes in MCF-10A acini, and tumor aggressiveness. Biomed Res Int (2013) 0.85

Inhibition of specific NF-κB activity contributes to the tumor suppressor function of 14-3-3σ in breast cancer. PLoS One (2012) 0.85

Regulatory T cells turn pathogenic. Cell Mol Immunol (2015) 0.85

Constitutive expression of TNF-related activation-induced cytokine (TRANCE)/receptor activating NF-κB ligand (RANK)-L by rat plasmacytoid dendritic cells. PLoS One (2012) 0.85

Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. J Oncol (2013) 0.84

Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration. Breast Cancer Res (2012) 0.83

Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study. Eur J Epidemiol (2014) 0.82

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. Vaccines (Basel) (2016) 0.82

Opposed expression of IKKα: loss in keratinizing carcinomas and gain in non-keratinizing carcinomas. Oncotarget (2015) 0.82

A seven-gene CpG-island methylation panel predicts breast cancer progression. BMC Cancer (2015) 0.82

Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse. J Carcinog (2011) 0.82

Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate. Front Immunol (2015) 0.82

Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. J Cancer Res Clin Oncol (2012) 0.82

Role of the nervous system in cancer metastasis. Oncol Lett (2013) 0.81

RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Res (2015) 0.81

CXCL13 activation of c-Myc induces RANK ligand expression in stromal/preosteoblast cells in the oral squamous cell carcinoma tumor-bone microenvironment. Oncogene (2012) 0.80

New and emerging factors in tumorigenesis: an overview. Cancer Manag Res (2015) 0.80

Molecular response of the axillary lymph node microenvironment to metastatic colonization. Clin Exp Metastasis (2014) 0.80

Immune regulation of bone metastasis. Bonekey Rep (2014) 0.80

Expression of pim-1 in tumors, tumor stroma and tumor-adjacent mucosa co-determines the prognosis of colon cancer patients. PLoS One (2013) 0.80

LGR5 expression is controled by IKKα in basal cell carcinoma through activating STAT3 signaling pathway. Oncotarget (2016) 0.80

Tumour progression and metastasis. Ecancermedicalscience (2016) 0.79

Obesity-associated NLRC4 inflammasome activation drives breast cancer progression. Nat Commun (2016) 0.79

Inflammation and skeletal metastasis. Bonekey Rep (2015) 0.79

The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases. Oncotarget (2016) 0.79

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 38.57

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55

Immunity, inflammation, and cancer. Cell (2010) 28.27

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A (1992) 8.59

CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell (2009) 8.54

Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol (2006) 6.23

RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78

Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27

The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell (2000) 4.53

Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01

Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37

Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 3.22

IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell (2001) 3.10

B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol (2006) 2.56

Structure and functional expression of the human macrophage inflammatory protein 1 alpha/RANTES receptor. J Exp Med (1993) 2.49

Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One (2009) 2.47

Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res (2010) 2.15

IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci U S A (2007) 2.09

Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res (1999) 1.93

Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol (2008) 1.26

Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunol Immunother (2008) 1.10

HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res (1992) 1.04

Immunity, inflammation, and cancer. Cell (2010) 28.27

Missing pieces in the NF-kappaB puzzle. Cell (2002) 17.83

A central role for JNK in obesity and insulin resistance. Nature (2002) 17.27

IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91

IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med (2005) 12.07

Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol (2009) 11.76

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52

The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol (2004) 10.85

AP-1 as a regulator of cell life and death. Nat Cell Biol (2002) 10.10

Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell (2005) 9.16

Regulation and function of IKK and IKK-related kinases. Sci STKE (2006) 8.98

IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell (2005) 8.78

A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54

Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol (2007) 8.29

Intracellular pattern recognition receptors in the host response. Nature (2006) 8.04

Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45

p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88

Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell (2008) 6.83

A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76

Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature (2009) 6.67

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36

Inflammation and colon cancer. Gastroenterology (2010) 6.32

Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24

Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol (2011) 6.17

NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature (2008) 6.13

Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature (2005) 5.72

The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 5.38

JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab (2007) 5.38

Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science (2005) 5.25

The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell (2006) 5.18

NF-κB and the link between inflammation and cancer. Immunol Rev (2012) 4.74

Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature (2007) 4.68

NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61

Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59

NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell (2007) 4.56

Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res (2007) 4.48

MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol (2008) 4.45

Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature (2012) 4.41

Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol (2008) 4.33

IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature (2005) 4.31

An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell (2011) 4.29

Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science (2002) 4.26

NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10

Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2009) 4.10

IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07

Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00

Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell (2004) 3.98

Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol Cell (2004) 3.94

Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies. Science (2010) 3.86

The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat Med (2003) 3.85

Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80

Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol (2013) 3.77

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest (2010) 3.74

A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell (2004) 3.71

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68

Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science (2004) 3.66

Retracted MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem (2008) 3.63

Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62

Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell (2008) 3.58

Redundant pathways for negative feedback regulation of bile acid production. Dev Cell (2002) 3.51

Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A (2011) 3.45

Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res (2006) 3.42

The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell (2008) 3.35

Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci U S A (2006) 3.33

Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J (2004) 3.32

A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A (2008) 3.27

Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A (2007) 3.26

B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24

The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature (2004) 3.18

IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity (2003) 3.12

Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08

Nestin expression in hair follicle sheath progenitor cells. Proc Natl Acad Sci U S A (2003) 3.07

Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05

Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proc Natl Acad Sci U S A (2006) 3.02

Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99

Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science (2008) 2.99

Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell (2008) 2.98

Retracted Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J Biol Chem (2002) 2.97

Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell (2010) 2.89

Retracted Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem (2003) 2.89

Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res (2009) 2.80

Multipotent nestin-positive, keratin-negative hair-follicle bulge stem cells can form neurons. Proc Natl Acad Sci U S A (2005) 2.78

Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A (2005) 2.76

Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis (2011) 2.74

Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology (2008) 2.70

A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell (2009) 2.64

Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis--CREB and NF-kappaB as key regulators. Immunity (2005) 2.56

Immunity by ubiquitylation: a reversible process of modification. Nat Rev Immunol (2005) 2.56

Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat Immunol (2009) 2.52